| |
CD
|
UC
|
controls
|
|---|
| |
All CD patients (n = 169)
|
ASCA negative CD patients (n = 109)
|
(n = 102)
|
(n = 225)
|
|---|
|
Anti-GP2 IgA, (%)
|
22 (13.0)
|
9 (8.2)
|
2 (2.0)
|
3 (1.3)
|
|
Anti-GP2 IgG, (%)
|
48 (28.4)
|
25 (22.9)
|
8 (7.8)
|
6 (2.7)
|
|
Anti-GP2 IgA and/or IgG, (%)
|
51 (30.2)
|
26 (23.9)
|
9 (8.8)
|
9 (4.0)
|
|
PAB > = 1/20, (%)
|
74 (43.8)
|
45 (41.3)
|
24 (23.5)
|
nd
|
|
PAB > = 1/40, (%)
|
65 (38.5)
|
38 (34.9)
|
21 (20.6)
|
nd
|
|
ASCA IgA, (%)
|
39 (23.1)
|
-
|
3 (2.9)
|
2 (0.9)
|
|
ASCA IgG, (%)
|
48 (28.4)
|
-
|
5 (4.9)
|
7 (3.1)
|
|
ASCA IgA and/or IgG, (%)
|
60 (35.5)
|
-
|
7 (6.9)
|
8 (3.5)
|
|
ASCA and/or anti-GP2, (%)
|
86 (50.9)
|
-
|
15 (14.7)
|
16 (7.1)
|
|
Number of positive antibodies detected by ELISA
| | | | |
|
0
|
83 (49.1)
|
83 (76.1)
|
87 (85.3)
|
208 (92.4)
|
|
1
|
40 (23.7)
|
18 (16.5)
|
12 (11.8)
|
13 (5.8)
|
|
2
|
28 (16.6)
|
8 (7.3)
|
3 (2.9)
|
4 (1.8)
|
|
3
|
11 (6.5)
|
-
|
0 (0.0)
|
0 (0.0)
|
|
4
|
7 (4.1)
|
-
|
0 (0.0)
|
0 (0.0)
|
- ASCA, antibody to mannan of Saccharomyces cerevisiae; CI, confidence interval; GP2, zymogen granule membrane glycoprotein 2; nd, not done; PAB, pancreatic autoantibody.
